SG11202010531SA - Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination - Google Patents
Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccinationInfo
- Publication number
- SG11202010531SA SG11202010531SA SG11202010531SA SG11202010531SA SG11202010531SA SG 11202010531S A SG11202010531S A SG 11202010531SA SG 11202010531S A SG11202010531S A SG 11202010531SA SG 11202010531S A SG11202010531S A SG 11202010531SA SG 11202010531S A SG11202010531S A SG 11202010531SA
- Authority
- SG
- Singapore
- Prior art keywords
- zika
- vaccination
- potent
- cross
- specific
- Prior art date
Links
- 241000907316 Zika virus Species 0.000 title 2
- 208000020329 Zika virus infectious disease Diseases 0.000 title 2
- 241000710829 Dengue virus group Species 0.000 title 1
- 208000001455 Zika Virus Infection Diseases 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662211P | 2018-04-24 | 2018-04-24 | |
| US201862697347P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/028952 WO2019209974A2 (en) | 2018-04-24 | 2019-04-24 | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010531SA true SG11202010531SA (en) | 2020-11-27 |
Family
ID=68293655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010531SA SG11202010531SA (en) | 2018-04-24 | 2019-04-24 | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11884718B2 (en) |
| BR (1) | BR112020021928A2 (en) |
| CA (1) | CA3098373A1 (en) |
| SG (1) | SG11202010531SA (en) |
| WO (1) | WO2019209974A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023133361A2 (en) * | 2022-01-10 | 2023-07-13 | Phenomic Ai | Anti-cthrc1 fusion proteins and methods of using the same |
| WO2023235660A2 (en) * | 2022-05-17 | 2023-12-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Flavivirus immunogens and vaccine compositions and methods of using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1778879A4 (en) | 2004-06-21 | 2010-02-24 | Univ Washington | Antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| US10208108B2 (en) * | 2014-11-28 | 2019-02-19 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to ricin toxin |
| US10086061B2 (en) * | 2015-03-11 | 2018-10-02 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| US10888613B2 (en) * | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| TW201815821A (en) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | Anti-zika virus antibodies and methods of use |
| JP2019533993A (en) | 2016-09-19 | 2019-11-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Combination of a novel vaccine against Zika virus with a DNA antibody construct for use against Zika virus |
| MY191894A (en) | 2016-10-13 | 2022-07-18 | Nat Univ Singapore | Antibodies that bind zika virus envelope protein and uses thereof |
| WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
-
2019
- 2019-04-24 CA CA3098373A patent/CA3098373A1/en active Pending
- 2019-04-24 BR BR112020021928-2A patent/BR112020021928A2/en unknown
- 2019-04-24 SG SG11202010531SA patent/SG11202010531SA/en unknown
- 2019-04-24 US US17/049,800 patent/US11884718B2/en active Active
- 2019-04-24 WO PCT/US2019/028952 patent/WO2019209974A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020021928A2 (en) | 2021-05-04 |
| CA3098373A1 (en) | 2019-10-31 |
| US20210238262A1 (en) | 2021-08-05 |
| US11884718B2 (en) | 2024-01-30 |
| WO2019209974A3 (en) | 2019-11-28 |
| WO2019209974A2 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262710A (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| MX2021007679A (en) | Human antibodies to influenza hemagglutinin. | |
| IL271231A (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
| IL266101A (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| IL284044A (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| SG11201605691VA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
| IL277375A (en) | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use | |
| ZA202007649B (en) | Virus and antigen purification and conjugation | |
| EP4028417A4 (en) | Anti-oncolytic virus antigen antibodies and methods of using same | |
| SG11202010531SA (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination | |
| EP3515482A4 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| SG10201912925SA (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| IL275296A (en) | Epstein-barr virus antigen constructs | |
| EA201592298A1 (en) | HUMAN VIRAL VACCINE AGAINST THE RESPIRATORY SYNCTIAL VIRUS | |
| EP4063383A4 (en) | Anti-varicella-zoster virus antibody | |
| IL272094A (en) | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection | |
| WO2017053525A3 (en) | Influenza vaccine and therapy | |
| HUE059264T2 (en) | Method for the immunological dosing of specific antibodies of antigens of viruses of thepoxviridae | |
| EA201592299A1 (en) | HUMAN VIRAL VACCINE AGAINST THE RESPIRATORY SYNCTIAL VIRUS | |
| MX2022005498A (en) | Zika/dengue vaccine and application thereof. | |
| EP4021503A4 (en) | Compositions and methods related to human neutralizing antibodies to hepatitis b | |
| IN2014DN07152A (en) | ||
| EP4061422A4 (en) | Human antibodies that neutralize zika virus and methods of use therefor | |
| IL259451A (en) | Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens |